Under the deal, Genentech will sequence the whole genomes of about 3,000
people with Parkinson’s disease in 23andMe’s database, and use that
data to look for new therapeutic targets that could treat the
neurodegenerative condition. The companies did not disclose financial
terms, but a spokeswoman confirmed that 23andMe will receive $10 million
initially and up to $50 million in future milestone.
- More Here
It's about time!! This was the reason I signed up 23andme few years ago. Big data isn't of much use if its not used to make life on this planet pleasant for all species.
I cannot wait for people to "freak out" because of this deal. Remember, these are the same people who will snore with the most profound security over the torture of a hundred millions of animals in the name of developing a pill to "cure" Hangover leave alone Parkinson's.
- More Here
It's about time!! This was the reason I signed up 23andme few years ago. Big data isn't of much use if its not used to make life on this planet pleasant for all species.
I cannot wait for people to "freak out" because of this deal. Remember, these are the same people who will snore with the most profound security over the torture of a hundred millions of animals in the name of developing a pill to "cure" Hangover leave alone Parkinson's.
No comments:
Post a Comment